U.S. markets close in 25 minutes
  • S&P 500

    4,433.83
    -39.92 (-0.89%)
     
  • Dow 30

    34,573.07
    -178.25 (-0.51%)
     
  • Nasdaq

    15,031.44
    -150.49 (-0.99%)
     
  • Russell 2000

    2,225.37
    -7.54 (-0.34%)
     
  • Crude Oil

    72.02
    -0.59 (-0.81%)
     
  • Gold

    1,753.00
    -3.70 (-0.21%)
     
  • Silver

    22.42
    -0.37 (-1.64%)
     
  • EUR/USD

    1.1734
    -0.0037 (-0.32%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3742
    -0.0055 (-0.40%)
     
  • USD/JPY

    109.9410
    +0.2230 (+0.20%)
     
  • BTC-USD

    47,292.30
    -427.71 (-0.90%)
     
  • CMC Crypto 200

    1,198.26
    -27.27 (-2.23%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.

Details of the event are as follows:

Panel:

Gamma Delta CART-Cells, and “Squeezed” T-cells

Date:

Thursday, April 15, 2021

Time:

1:00 – 1:55 PM ET

Format:

Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com